SYK Earnings Prediction
The chart below shows how SYK performed 10 days before and after its earnings report, based on data from the past quarters. Typically, SYK sees a -1.15% change in stock price 10 days leading up to the earnings, and a +1.17% change 10 days following the report. On the earnings day itself, the stock moves by +0.32%. This data can give you a slight idea of what to expect for the next quarter's release.
SYK Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
6.44B
10.68%
17.15%
Gross Margin
62.90%
2.63%
2.09%
Operating Margin
26.07%
3.41%
17.22%
Net Margin
8.48%
-56.87%
-44.14%
EPS
1.41
-52.68%
-34.72%
No Data Available
SYK Earnings Analysis
Stryker Corp Corporation (SYK.N) Earnings Conference Call
Positive
Strong Organic Sales Growth: Organic sales growth exceeded 10% for both the quarter and the full year, with U.S. organic sales growth at 10.6% and international growth at 8.8%.
Adjusted EPS Growth: Adjusted EPS for the quarter was $4.01, reflecting a 16% increase year-over-year, while full year adjusted EPS reached $12.19, a 15% growth compared to 2023.
Operating Margin Improvement: The company achieved an adjusted operating margin improvement of 200 basis points for the quarter and 110 basis points for the full year, reaching 29.2% and 25.3% respectively.
Robotic System Adoption: The Mako robotic system saw significant adoption, with approximately two-thirds of knee procedures and one-third of hip procedures performed using Mako in the U.S. by year-end.
Market Position Enhancement: The acquisition of Inari Medical is expected to enhance Stryker's position in the mechanical thrombectomy market, which represents a $15 billion addressable opportunity globally.
Negative
Sales Growth Slowdown: Organic sales growth decreased to 10.2% in the fourth quarter compared to 11.4% in the previous quarter, indicating a slowdown in growth momentum.
Spinal Implants Growth Challenges: The U.S. Spinal Implants business only grew 2.3% organically in the quarter, significantly lagging behind other segments and reflecting ongoing challenges in performance expectations.
Increased Other Income Expense: Adjusted other income expense for the quarter was $51 million, which was $20 million higher than the previous year, primarily due to increased interest expenses from a recent debt issuance.
Currency Impact on Earnings: Foreign currency translation negatively impacted adjusted earnings per share by approximately $0.13 for the full year, highlighting the adverse effects of currency fluctuations on financial results.
Acquisition Impact Analysis: The pending acquisition of Inari Medical is expected to have a dilutive impact on adjusted operating margin of 20 basis points and adjusted EPS by $0.10 to $0.15, indicating potential challenges in achieving desired financial performance post-acquisition.
SYK FAQs
How does SYK typically perform around its earnings report dates?
Is Stryker Corp (SYK) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
SYK Earning Call Sentiment
Earnings call transcript: Stryker Q4 2024 earnings beat forecasts
SYK.N
-0.72%Positive
The earnings call presents a mixed picture. Strong financial metrics and EPS growth are positives, but the lack of share buybacks and potential dilution from the Inari acquisition are concerns. Despite optimistic guidance and margin expansion, the unclear details on the Spine sale and Inari's ROI create uncertainty. With no major catalysts and some caution from analysts, the stock is likely to experience a neutral reaction.
